EU follows U.S. lead in studying diabetes drugs risks
LONDON, March 26
LONDON, March 26 (Reuters) - The European Medicines Agency said on Tuesday it was investigating the possibility that two widely used classes of diabetes drugs might cause inflammation of the pancreas and pre-cancerous changes.
The decision to study so-called GLP-1 therapies and DPP-4 drugs follows similar action earlier this month by the U.S. Food and Drug Administration.
Drugs affected include Novo Nordisk's Victoza, Merck & Co's Januvia, and Onglyza from Bristol-Myers Squibb and AstraZeneca.
- Malaysia Airlines plane missing at sea off Vietnam, presumed crashed |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Fresh confrontations raise tempers on ground in Crimea |
- Malaysian plane crashed off Vietnam coast: state media